PubMed

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

Schneider BP, Sledge GW Jr.

Breast Cancer Res. 2009;11(3):303. Epub 2009 May 18.PMID: 19519950 [PubMed - indexed for MEDLINE]Related articlesFree article

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

Hsu JY, Wakelee HA.

BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000. Review.PMID: 19754219 [PubMed - indexed for MEDLINE]Related articles

Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.

Grothey A.

Semin Oncol. 2006 Oct;33(5 Suppl 10):S41-9. Review.PMID: 17145524 [PubMed - indexed for MEDLINE]Related articles

Vascular endothelial growth factor and bevacitumab in breast cancer.

Bando H.

Breast Cancer. 2007;14(2):163-73. Review.PMID: 17485901 [PubMed - indexed for MEDLINE]Related articlesFree article

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Tortora G, Ciardiello F, Gasparini G.

Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. Epub 2008 Jul 1. Review.PMID: 18594498 [PubMed - indexed for MEDLINE]Related articles

Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.

Harmey JH, Bouchier-Hayes D.

Bioessays. 2002 Mar;24(3):280-3. Review.PMID: 11891765 [PubMed - indexed for MEDLINE]Related articles

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.PMID: 18221053 [PubMed - indexed for MEDLINE]Related articles

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

Kerbel RS, Viloria-Petit A, Klement G, Rak J.

Eur J Cancer. 2000 Jun;36(10):1248-57. Review.PMID: 10882863 [PubMed - indexed for MEDLINE]Related articles

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. Epub 2009 Jun 30.PMID: 19567820 [PubMed - indexed for MEDLINE]Related articles

Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

Venook AP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. Review.PMID: 19780248 [PubMed - indexed for MEDLINE]Related articles

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

Pegram MD, Reese DM.

Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37. Review.PMID: 12138395 [PubMed - indexed for MEDLINE]Related articles

[Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer]

Ueno Y.

Nippon Jibiinkoka Gakkai Kaiho. 2006 Mar 20;109(3):163-70. Japanese. PMID: 16615431 [PubMed - indexed for MEDLINE]Related articles

Angiogenesis inhibitors in the treatment of lung cancer.

Sun S, Schiller JH.

Crit Rev Oncol Hematol. 2007 May;62(2):93-104. Epub 2007 Feb 15. Review.PMID: 17306557 [PubMed - indexed for MEDLINE]Related articles

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. Review.PMID: 18536556 [PubMed - indexed for MEDLINE]Related articles

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS.

Am J Pathol. 1997 Dec;151(6):1523-30.PMID: 9403702 [PubMed - indexed for MEDLINE]Related articlesFree article

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.PMID: 12516032 [PubMed - indexed for MEDLINE]Related articles

Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches.

Kuhn H, Hammerschmidt S, Wirtz H.

Curr Med Chem. 2007;14(30):3157-65. Review.PMID: 18220749 [PubMed - indexed for MEDLINE]Related articles

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. Epub 2008 Oct 23. Review.PMID: 18948057 [PubMed - indexed for MEDLINE]Related articles

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Langer CJ, Natale RB.

Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. Review.PMID: 16459176 [PubMed - indexed for MEDLINE]Related articles

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

Marty M, Pivot X.

Eur J Cancer. 2008 May;44(7):912-20. Epub 2008 Apr 7. Review.PMID: 18396037 [PubMed - indexed for MEDLINE]Related articles